AACR 2025 – Merck's head and neck headscratcher
Keynote-689 delivers a win in all-comers, but how did PD-L1-negatives do?
AUA 2025 – J&J scores in a new bladder cancer use
But the company is awaiting pivotal results with TAR-200 in papillary disease before filing.
Ivo combo beats Tevimbra, but can it beat Keytruda?
The PD-1 x VEGF molecule's latest win comes from Akeso's Harmoni-6 trial.
Trodelvy gets one up on Datroway in triple-negative breast
Gilead’s TROP2 ADC prevails in Ascent-04, in first-line PD-L1-positive TNBC.
J&J broadens its bladder cancer push
TAR-210's latest non-muscle invasive bladder cancer phase 3 setting is post-BCG.
Enhertu could fill a gastric hole
The first-line Destiny-Gastric05 trial includes a PD-L1-negative cohort.
